Citations: Bendamustine - A New Approach to the Treatment of Advanced Hepatocellular Carcinoma?

Views

CrossRef citations to date

Altmetric

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Frank Herting, Thomas Friess, Sabine Bader, Gunter Muth, Gabriele Hölzlwimmer, Natascha Rieder, Pablo Umana & Christian Klein. (2014) Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leukemia & Lymphoma 55:9, pages 2151-5160.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bendamustine - A New Approach to the Treatment of Advanced Hepatocellular Carcinoma?

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bendamustine - A New Approach to the Treatment of Advanced Hepatocellular Carcinoma?

Citations (1)

Read on this site (1)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date